1394/2007: Legal framework for ATMPs in the EU.

These definitions are crucial for RA professionals to determine the correct regulatory pathway for ATMP submissions.

Global Frameworks Governing ATMPs

ATMP classification is governed by distinct but harmonizing frameworks:

• EMA (EU): Defines ATMPs under EC No 1394/2007, with the Committee for Advanced Therapies (CAT) responsible for classification and scientific advice.
• FDA (US): Regulates ATMPs through the Center for Biologics Evaluation and Research (CBER) under 21 CFR Parts 1271, 600, and 601.
• CDSCO (India): Draft cell and gene therapy guidelines (2021) propose classification based on EMA/FDA standards.
• WHO & ICH: Global initiatives to harmonize ATMP definitions and regulatory standards.

RA professionals must map ATMP definitions to regional frameworks to ensure compliance and avoid classification errors.

Processes and Workflow for ATMP Classification

ATMP classification follows a structured process:

1. Initial Assessment: Determine if product fits gene therapy, cell therapy, or tissue-engineered definitions.
2. Scientific Advice: Seek early consultation with EMA CAT, FDA CBER, or CDSCO expert committees.
3. Dossier Preparation: Document scientific rationale, mechanism of action, and product composition.
4. Formal Classification: Submit classification request to EMA CAT or FDA CBER for official designation.
5. Regulatory Pathway Selection: Align classification with applicable submission type (BLA, MAA, IND/CTA).
6. Lifecycle Integration: Ensure classification remains valid during clinical development and post-approval changes.

This workflow helps ensure regulatory clarity before significant development investments are made.

Case Study 1: EMA ATMP Classification

Case: A European biotech sought classification for a chondrocyte-based cartilage repair therapy.

• Challenge: Uncertainty if product met tissue-engineered definition.
• Action: Submitted classification request to EMA CAT with preclinical evidence of tissue regeneration.
• Outcome: CAT classified therapy as TEP under ATMP framework.
• Lesson Learned: Early engagement with CAT avoids misclassification and delays.

Case Study 2: FDA Gene Therapy Designation

Case: A US biotech developed a CRISPR-based gene therapy for a rare metabolic disorder.

• Challenge: Unclear if classified as biologic or ATMP.
• Action: Consulted FDA CBER, which confirmed gene therapy classification under 21 CFR 601.
• Outcome: Developer aligned submission as a BLA, ensuring correct review pathway.
• Lesson Learned: Classification confirmation is critical for aligning regulatory strategy.

Tools, Templates, and Systems Used

ATMP classification requires structured documentation:

• EMA CAT Templates: Formal classification request forms with detailed product descriptions.
• FDA CBER Guidance: Checklists and frameworks for cell and gene therapy classification.
• Comparative Matrices: Tools mapping definitions across EU, US, and India frameworks.
• RIM Systems: Track ATMP classification requests and regulatory communications globally.
• Scientific Rationale Templates: Standardized documents capturing mechanism of action and intended use.

These tools help ensure consistency and inspection readiness for ATMP regulatory pathways.

Common Challenges and Best Practices

Classification of ATMPs involves several hurdles:

• Novel Mechanisms: Innovative therapies may not fit neatly into existing definitions.
• Global Variability: Differences between FDA, EMA, and CDSCO frameworks increase complexity.
• Regulatory Uncertainty: Ambiguity in early development stages may delay submissions.
• Resource Burden: Preparing classification dossiers requires significant scientific and regulatory effort.

Best practices include seeking early scientific advice, harmonizing definitions across agencies, documenting robust scientific rationales, and engaging with regulatory committees early in development.

Latest Updates and Strategic Insights

As of 2025, ATMP classification is evolving with new trends:

• CRISPR Therapies: Growing number of CRISPR-based products classified as ATMPs.
• Global Harmonization: ICH initiatives aiming to standardize ATMP definitions across major regions.
• Digital Tools: AI-based classification models assisting regulatory teams in mapping product categories.
• Hybrid Products: Increasing prevalence of combined ATMPs integrating biologics and devices.
• Inspection Focus: Regulators emphasizing classification accuracy during GMP and dossier audits.

Strategically, RA professionals must anticipate classification challenges early, leverage harmonization initiatives, and adopt innovative tools for compliance readiness.

Conclusion

ATMP classification and definitions form the foundation of regulatory strategy for cell, gene, and tissue therapies. By mastering EMA, FDA, and CDSCO frameworks, RA professionals can avoid misclassification risks, align submission strategies, and accelerate patient access to breakthrough therapies. In 2025 and beyond, accurate ATMP classification will remain critical to regulatory success and innovation in advanced therapies.